India Gets Cheaper GLP-1 Therapy for Diabetes

Glenmark Pharmaceuticals has introduced GLIPIQ, a semaglutide-based treatment for Type 2 Diabetes Mellitus, in India. This launch aims to significantly enhance the affordability of GLP-1 therapies, addressing a key barrier to advanced diabetes management. The company's initiative seeks to enable earlier treatment initiation for a wider patient population.

The drug received approval from the Central Drugs Standard Control Organization (CDSCO) after a successful Phase III clinical study conducted in India. GLIPIQ is available in two forms: a vial-based version for flexible, physician-guided dosing, and a pre-filled pen for convenient self-administration. The vial formulation is notably cost-effective, with weekly therapy costing between Rs 325 and Rs 440.

To further support patients, Glenmark has launched 'Sankalp,' a patient assistance program. This initiative is designed to facilitate therapy initiation, build confidence with injectable treatments, and foster long-term adherence. Semaglutide, as a GLP-1 receptor agonist, is recognized for its benefits beyond glycemic control, including positive impacts on cardiovascular health and kidney function.